Press Release January 10, 2014 Extra bolagsstämma har hållits i Russian Real Estate Investment Company AB (publ) Extraordinary general meeting has been held in Russian Real Estate Investment Company AB (publ) Den 10 januari 2014 har extra bolagsstämma hållits i Russian Real Estate Investment Company AB (publ) ("Ruric" eller "Bolaget"). Den extra bolagsstämman beslutade om minskning av Bolagets aktiekapital i enlighet med styrelsens förslag enligt följande villkor. On 10 January 2014, an extraordinary general meeting was held in Russian Real Estate Investment Company AB (publ) ("Ruric" or the "Company"). The extraordinary general meeting resolved on the reduction of the Company's share capital in accordance with the Board of Directors' proposal on the following terms. 1. Minskningsändamålet är täckning av förlust. The purpose of the reduction shall be to cover losses. 2. Aktiekapitalet ska minskas med 180 371 388 kronor. Efter att bolagsstämmans beslut registrerats kommer Bolagets aktiekapital att uppgå till 80 000 000 kronor. The share capital shall be reduced with SEK 180,371,388. After the resolution of the meeting has been registered, the Company's share capital will be SEK 80,000,000. 3. Minskningen ska genomföras utan indragning av aktier. Antalet aktier i Bolaget är 130 185 694 fördelat på 1 330 266 aktier av serie A och 128 855 428 aktier av serie B. Om bolagsstämman beslutar i enlighet med styrelsens förslag kommer aktiernas kvotvärde efter registrering av den föreslagna minskningen således att minska från 2 kronor till cirka 0,61450 kronor. The reduction shall be made without redemption of shares. The number of shares in the Company is 130,185,694 divided between 1,330,266 class A shares and 128,855,428 class B shares. If the meeting resolves in accordance with the Board of Directors' proposal, the quota value of the shares will be reduced from SEK 2 per share to approximately SEK 0,61450 per share after registration. Skälen för styrelsens förslag / The reasons for the Board of Directors' proposal Skälen för styrelsens förslag till minskning av Bolagets aktiekapital är för att skapa förutsättningar för att Bolagets eget kapital enligt den kontrollbalansräkning som upprättas för den andra kontrollstämman enligt 25 kap. 14 och 16 §§ aktiebolagslagen ska uppgå till minst det registrerade aktiekapitalet vid tiden för den andra kontrollstämma som ska hållas inom åtta (8) månader från den dag den första kontrollstämman hölls (den stämman hölls den 28 juni 2013). The reason for the Board of Directors' proposal to reduce the Company's share capital is to facilitate that the Company's equity in accordance with the liquidation balance sheet to be established for the second meeting for liquidation purposes in accordance with Chapter 25 Sections 14 and 16 of the Swedish Companies Act is more than the registered share capital at the time of the second meeting for liquidation purposes, which is to be held within eight (8) months from the date of the initial meeting for liquidation purposes (which was held on 28 June 2013). For additional information: Tatiana Ottestig, CEO Tel.: +7 (812) 309-78-95 E-mail: tottestig@ruric.com Web: www.ruric.com About Ruric: RURIC AB (Russian Real Estate Investment Company AB (publ) (reg. no. 556653-9705, Lindhagensgatan 94, SE-112 18 Stockholm)) is a public limited liability company incorporated under the laws of Sweden, operating in the St. Petersburg commercial real estate market since 2004. The company is dealing with the investment projects coordination, local and national market approach consulting, valuation and property trust services. Real estate portfolio construction and management services are also included. RURIC's Certified Advisor at First North is Erik Penser Bankaktiebolag [HUG#1753994]
Extraordinary general meeting has been held in Russian Real
Top 10 Most Recent News Articles
Kelun-Biotech's Sacituzumab Tirumotecan Shows Promise in NSCLC
Kelun-Biotech's Recent Breakthrough Grab your coffee, and let's chat about something that might just change the lung cancer treatment game: Kelun-Biotech's sacituzumab tirumotecan, or sac-TMT, showing some serious promise in a Phase III trial. With numbers that could make any investor sit up a little straighter, this study has turned heads at the European Society for...
Continue Reading
Community in Shock After Fatal Bakersfield Shooting
The Ripple Effect of Tragedy Grief has a way of shaking a community down to its core—especially when the loss emanates from such senseless violence as the shooting death of 17-year-old Levi Brown. This wasn't just a tragic occurrence at a Friday night football game in Bakersfield; it was a visceral crack in the perceived safety of community events. Levi's Legacy and...
Continue Reading
Vantrue's Black Friday Dash Cam Deals: Save up to 44%
Kicking Off Early Black Friday with Dash Cam Bargains In a bid to stay ahead of the holiday shopping rush, Vantrue announced its early Black Friday campaign with a range of discounts designed to capture the interest of road warriors and casual drivers alike. From November 1 to November 21, 2026, Vantrue is inviting bargain hunters to explore their offerings—culminating...
Continue ReadingFirefox Champions Privacy with Iconic Internet Campaign
Rekindling the Internet’s Golden Days with Firefox There’s something almost poetic about Firefox hustling to win back its old users by launching a campaign with legendary internet icons. The backdrop? A digital landscape where privacy feels about as common as a unicorn sighting. Mozilla's pulling a major nostalgia card, and I'm here for it—sort of like how vinyl...
Continue Reading
Johnson & Johnson's JNJ-6143 Shines in Prostate Cancer Study
Prostate Cancer's Persistent Challenge No one in the healthcare game needs the reminder: prostate cancer is no walk in the park, especially for those grappling with advanced stages. Now picture this—you're on your sixth treatment, and the cloud is not lifting. It's a battle that never ends, with traditional therapies sometimes barely holding the line. JNJ-6143's New...
Continue Reading
Innovent's IBI354: New Data Spurs Hope for HER2+ BC
Innovent Lauds HER2 ADC's Moment at ESMO 2026 Alright, chin up, investors. At the 2026 ESMO Congress, Innovent's throwing down some promising Phase 2 data for their brainchild, IBI354. You hear that name and it's like hearing about a rock star in the making in the oncology world. The potential here isn’t just talk—it's a loud, resounding call for attention. Their...
Continue Reading
Sinclair Faces Labor Lawsuit for Break-time Violations
Sinclair Television Caught in Labor Law Storm When you think of flaring tempers and boardroom brawls, you typically don't think of your everyday TV station. But right now, Sinclair Television of California, LLC is in the hot seat, accused of playing fast and loose with wage packets—specifically, allegedly denying meal periods and rest breaks that California labor laws...
Continue Reading
Ping An's Bold Green Moves Ahead of APEC 2026
Ping An's Pitch for Green: Talking the Talk and Walking the Walk? Well, here's something cooking in Shenzhen at the Ping An Finance Center—an international seminar championing green development initiatives. It's all buzz around Ping An Insurance (HKEX: 2318; SSE: 601318) flexing its green muscle, orchestrating conversations right before APEC 2026. Talk about timing....
Continue Reading
Lilly's Olomorasib: New Data Sparks Hope for G12C NSCLC
New Data Unveiling Potential Shifts in NSCLC Treatment Man, if there's one thing the oncology world craved, it's progress against KRAS G12C-mutant non-small cell lung cancer (NSCLC). We're talking about a challenge as tough as a two-dollar steak. But hey, Eli Lilly's (NYSE:LLY) putting some serious cards on the table with olomorasib, and folks at the ESMO 2026 Congress...
Continue Reading
Monster Energy Unleashes Gaming Frenzy at Cosm L.A. Event
Where Energy Drinks and Digital Reality Collide Monster Energy sure knows how to throw a party, especially when it hinges on something as electrifying as Call of Duty: Modern Warfare 4. Imagine this: Cosm Los Angeles is decked out with a massive 87-foot LED dome, and every gamer, celeb, and influencer ready to dive right in. You can't make this stuff up. They've mashed...
Continue ReadingTop 5 Most Recently Viewed Articles
Mobility Direct's Inspiring Journey in Supporting the Disabled
Empowering Mobility for a Decade Mobility Direct has reached a remarkable milestone, celebrating ten years of dedicated service to individuals facing mobility challenges. The company, based in Florida, has profoundly impacted the lives of many by providing free mobility scooters to those in need. With each scooter given, they challenge the common assumption that mobility...
Continue Reading
GARDANT GLOBAL Teams Up with GovConRx for Enhanced Services
GARDANT GLOBAL Forms Strategic Alliance with GovConRx GARDANT GLOBAL is thrilled to share exciting news about its latest partnership with GovConRx. This collaboration is set to transform the landscape of contract performance management for government contractors. GovConRx, well-known for its expertise in enhancing CPARS ratings, will significantly augment GARDANT's...
Continue Reading
Text Request and Commify Join Forces to Enhance Messaging Solutions
Text Request and Commify Join Forces to Enhance Messaging Solutions Text Request, a leader in the business text messaging domain, has recently announced an exciting new chapter following its acquisition by the U.K.-based Commify. This strategic move is aimed at expanding its reach within the U.S. market while maintaining its operational base in Chattanooga. Growth Journey...
Continue Reading
Agenus Investors Alerted on Class Action Lawsuit Developments
Levi & Korsinsky Notifies Investors of Class Action for Agenus Inc. Levi & Korsinsky, LLP is reaching out to investors in Agenus Inc. (NASDAQ: AGEN) regarding a significant class action lawsuit that may impact those financially affected by the company's alleged misrepresentations. This development is crucial for stakeholders who have invested in Agenus during the...
Continue Reading
Savvas Unveils Innovative Science Curriculum for Students
Introducing Experience Science for Grades K-8 In a groundbreaking initiative, Savvas Learning Company has launched Experience Science, an all-new program curated specifically for students in grades K-8. This innovative curriculum aims to engage young learners in scientific concepts, placing significant emphasis on hands-on experiences driven by real-world phenomena....
Continue Reading